Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 325 versus OMNIPAQUE 180.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 325 versus OMNIPAQUE 180.
CONRAY 325 vs OMNIPAQUE 180
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays by blocking photons, allowing visualization of blood vessels and tissues.
Iodinated contrast agent that radiates X-rays due to high iodine content, attenuating X-ray beams and enhancing vascular/tissue contrast.
Intravenous: 1.0-2.0 mL/kg (325 mg I/mL) for contrast imaging; maximum total dose 250 mL.
Intravenous: 50-200 mL of 180 mgI/mL (9-36 g iodine) administered as a bolus or infusion, depending on imaging procedure and patient size; typical CT dose: 100-150 mL.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. May be prolonged in renal impairment.
Terminal elimination half-life: 1-2 hours in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe impairment)
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<5%).
Renal: >95% unchanged by glomerular filtration within 24 hours; Biliary/Fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent